

Cerebrovascular events in adult Takayasu arteritis

Submission date 21/02/2025	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 27/02/2025	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 27/02/2025	Condition category Circulatory System	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Takayasu arteritis (TA) is a disease that causes inflammation in large blood vessels, mainly the aorta and its main branches. The cause of TA is unknown. Because TA is rare, we don't fully understand the symptoms and long-term effects in Chinese adults who have cardiovascular events (CVEs). This study aimed to (1) describe the clinical features of CVEs in adults with TA; and (2) summarize the treatment methods and outcomes for stroke patients, focusing on death rates and the chances of having another stroke or transient ischemic attack (TIA).

Who can participate?

Inpatients aged 18 years and over who were admitted to hospital with TA

What does the study involve?

The researchers reviewed the medical records of patients with TA who underwent aortic angiography, computed tomography angiogram (CTA) or magnetic resonance angiography (MRA) between January 2000 to December 2024. The incidence, clinical features, management strategy and prognosis of these patients were evaluated.

What are the possible benefits and risks of participating?

This is a retrospective study. There are no possible benefits or risks of participating.

Where is the study run from?

Affiliated Chuiyangliu Hospital of Tsinghua University.

When is the study starting and how long is it expected to run for?

January 2025 to February 2025

Who is funding the study?

Investigator initiated and funded

Who is the main contact?

Prof. Juntong Huo, huojuntong301@163.com

Contact information

Type(s)

Public, Principal Investigator

Contact name

Prof Junting Huo

Contact details

Chuiyangliu South Street 2

Beijing

China

100022

+86 (0)13321123960

huojunting301@163.com

Type(s)

Scientific

Contact name

Prof Linggen Gao

Contact details

100853 Fuxing Road 28

Beijing

China

100853

+86 (0)15801612879

gaolinggen@163.com

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

Nil known

Study information

Scientific Title

Clinical characteristics and outcomes of cerebrovascular events in adult Takayasu arteritis: a cohort study of 182 patients

Study objectives

Because of the rarity of Takayasu arteritis (TA), clinical characteristics and long-term outcomes of Chinese adult TA patients with cerebrovascular events (CVEs) have not been fully elucidated. This study aimed to:

1. Describe the ratio and clinical features of CVEs in adult TA patients
2. Summarize the therapeutic strategy and the prognosis of stroke patients, focusing on mortality and recurrence of stroke/transient ischaemic attack (TIA).

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 05/12/2024, Ethics committee of Chuiyangliu Hospital (Chuiyangliu South Street 2, Beijing, 100022, China; +86 (0)10 6770 0622; chuiyangliucyl@163.com), ref: SOP-CYLIRB-2.0

Study design

Observational cohort study

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Hospital

Study type(s)

Other

Participant information sheet

Not available in web format, please use the contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Cerebrovascular events in adult Takayasu arteritis

Interventions

The researchers retrospectively collected 1071 TA subjects and enrolled the patients with CVEs between January 2000 and December 2024. The incidence, clinical features, management strategy and prognosis of these patients were evaluated.

Intervention Type

Other

Primary outcome measure

All-cause mortality at 1, 6, 12 months and every year, collected from medical records

Secondary outcome measures

Recurrence of stroke/TIA at 1, 6, 12 months and every year, collected from medical records

Overall study start date

01/01/2025

Completion date

21/02/2025

Eligibility

Key inclusion criteria

Adult patients with TA fulfilling the criteria of the American College of Rheumatology

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Upper age limit

100 Years

Sex

Both

Target number of participants

150

Total final enrolment

182

Key exclusion criteria

Clinical remission criteria: absence of new symptoms and normalized erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)

Date of first enrolment

01/01/2000

Date of final enrolment

31/12/2024

Locations

Countries of recruitment

China

Study participating centre

Affiliated Chuiyangliu Hospital of Tsinghua University
Department of Neurology
Chuiyangliu South Street
Beijing
China
100022

Sponsor information

Organisation

Affiliated Chuiyangliu Hospital of Tsinghua University

Sponsor details

Chuiyangliu South Street 2
Beijing
China
100022
+86 (0)13051852879
wangjwcq@163.com

Sponsor type

Hospital/treatment centre

Website

<https://www.cylh.com/>

Funder(s)

Funder type

Other

Funder Name

Investigator initiated and funded

Results and Publications

Publication and dissemination plan

Planned publication in a peer-reviewed journal.

Intention to publish date

01/06/2025

Individual participant data (IPD) sharing plan

The participant-level data is expected to be made available in the published paper.

IPD sharing plan summary

Published as a supplement to the results publication